Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,517 across all filing types
Latest filing 2025-01-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Ltd regarding clinical trial approval for a new drug product by a regulatory authority. It does not relate to financial results, management changes, share transactions, dividends, or other specific categories. It is a general regulatory announcement, thus falling under the fallback category “Regulatory Filings (RNS).”
2025-01-07 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 94% confidence The document is a standardized “Next Day Disclosure Return” (Form FF305) filed under the Hong Kong Stock Exchange Listing Rules. It details changes in issued and treasury shares and reports on the company’s share repurchases (on-market buybacks). This is a report of the company buying back its own shares, matching the “Transaction in Own Shares” category.
2025-01-07 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 98% confidence The document is a Next Day Disclosure Return under the Hong Kong Stock Exchange listing rules (Main Board Rule 13.25A/GEM Rule 17.27A and Main Board Rule 10.06/GEM Rule 13.13), detailing changes in issued shares, treasury shares, and specifically share repurchase/cancellation transactions by the issuer. This is not a periodic financial report or earnings release but a corporate action notice regarding share buybacks, fitting the definition of a Transaction in Own Shares (share repurchase).
2025-01-06 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued shares and treasury shares, specifically reporting on share repurchases (on-market buybacks) and repurchases for cancellation. This constitutes a transaction in the company’s own shares. Under our taxonomy, reports of share buybacks or sales of treasury shares are classified as “Transaction in Own Shares” (POS).
2025-01-03 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is a Chinese Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, specifically listing multiple share repurchases for cancellation, prices, dates, and aggregate amounts. It is not announcing a dividend, AGM materials, or financial results, but is a formal disclosure of repurchase transactions by the issuer. This matches the “Transaction in Own Shares” category.
2025-01-02 English
VOLUNTARY ANNOUNCEMENT - SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the granting of Breakthrough Therapy Designation by China’s National Medical Products Administration for a drug candidate. It is not a financial report, earnings release, management discussion, or any structured regulatory form (e.g., 10-K, IR, ER). It does not announce dividends, share issues, M&A, board changes, or voting results. It is a general regulatory update and falls into the fallback category “Regulatory Filings” (RNS).
2025-01-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.